The nation’s potential fourth vaccine option proved a 90.4 percent efficacy rate against COVID-19 among adults and 80 percent efficacy among study participants 12 to 17 years old in phase 3 trials, according to the company’s press release.
On June 7, an independent FDA panel voted 21-0, with one absentee, to recommend Novavax’s vaccine for emergency use authorization for adults.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.